Leerink Swann restated their outperform rating on shares of Mallinckrodt PLC (NYSE:MNK) in a research report report published on Friday. The firm currently has a $92.00 price target on the stock, up from their prior price target of $91.00.

Analyst Recommendations for Mallinckrodt PLC (NYSE:MNK)

MNK has been the topic of several other research reports. Vetr lowered Mallinckrodt PLC from a buy rating to a sell rating and set a $61.84 price target on the stock. in a report on Monday, June 6th. BMO Capital Markets reiterated a buy rating and set a $84.00 price target on shares of Mallinckrodt PLC in a report on Tuesday, July 19th. Zacks Investment Research upgraded Mallinckrodt PLC from a hold rating to a buy rating and set a $71.00 price target on the stock in a report on Tuesday, July 19th. Barclays PLC lifted their price target on Mallinckrodt PLC from $75.00 to $88.00 and gave the stock an overweight rating in a report on Wednesday, August 3rd. Finally, JPMorgan Chase & Co. set a $85.00 price target on Mallinckrodt PLC and gave the stock a hold rating in a report on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Mallinckrodt PLC currently has a consensus rating of Buy and an average target price of $94.66.

Mallinckrodt PLC (NYSE:MNK) opened at 74.09 on Friday. The firm’s 50-day moving average is $77.16 and its 200 day moving average is $65.72. The company has a market capitalization of $7.98 billion, a PE ratio of 13.97 and a beta of 1.52. Mallinckrodt PLC has a one year low of $50.90 and a one year high of $85.83.

Mallinckrodt PLC (NYSE:MNK) last announced its earnings results on Tuesday, August 2nd. The company reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.00 by $0.20. Mallinckrodt PLC had a net margin of 16.39% and a return on equity of 17.78%. The company had revenue of $970.60 million for the quarter, compared to analysts’ expectations of $920.35 million. During the same quarter in the previous year, the company posted $2.05 EPS. The firm’s quarterly revenue was up .6% on a year-over-year basis. On average, equities analysts expect that Mallinckrodt PLC will post $7.67 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in MNK. Laurel Wealth Advisors Inc. boosted its stake in Mallinckrodt PLC by 0.5% in the second quarter. Laurel Wealth Advisors Inc. now owns 3,427 shares of the company’s stock valued at $208,000 after buying an additional 16 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in Mallinckrodt PLC by 1.2% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,472 shares of the company’s stock valued at $214,000 after buying an additional 41 shares during the period. Turner Investments L.P. boosted its stake in Mallinckrodt PLC by 0.5% in the second quarter. Turner Investments L.P. now owns 19,420 shares of the company’s stock valued at $1,180,000 after buying an additional 100 shares during the period. Investors Capital Advisory Services boosted its stake in Mallinckrodt PLC by 1.2% in the second quarter. Investors Capital Advisory Services now owns 8,710 shares of the company’s stock valued at $529,000 after buying an additional 107 shares during the period. Finally, LS Investment Advisors LLC boosted its stake in Mallinckrodt PLC by 2.4% in the second quarter. LS Investment Advisors LLC now owns 5,408 shares of the company’s stock valued at $329,000 after buying an additional 126 shares during the period. Institutional investors and hedge funds own 94.74% of the company’s stock.

Mallinckrodt PLC Company Profile

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.

5 Day Chart for NYSE:MNK

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.